Today, Paul MacDonald commented about whether AGN-N, UNH-N, REGN-Q, MRK-N, SNY-N, SYK-N, AZN-N, TEVA-N, CVS-N, BSX-N, MRK-N, AMGN-Q, ANTM-N, PFE-N, BMY-N, ABBV-N, SNN-N, GILD-Q are stocks to buy or sell.
BMY was going down before their Celgene purchase, which was a good deal (he owned Celgene) at a bargain. BMY didn't do anything particularly wrong; their drugs are doing well. However, Merck is the dominant player in this space with better science, and so is his preferred pick. Better to hold a basket of health stocks though to lessen risk in holding individual health stocks--science keeps changing.